𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Results of conventional-dose cytosine arabinoside and idarubicin in elderly patients with acute myeloid leukemia

✍ Scribed by A. Heyll; C. Aul; F. Gogolin; V. Runde; D. Söhngen; G. Meckenstock; H. -H. Wolf; J. Zahner; M. Burk; M. Winkelmann; W. Schneider

Publisher
Springer
Year
1994
Tongue
English
Weight
549 KB
Volume
68
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Idarubicin and standard-dose cytosine ar
Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia
✍ Merat Karbasian-Esfahani; Peter H. Wiernik; Yelena Novik; Elisabeth Paietta; Jan 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 1 views

## Abstract ## BACKGROUND Drug resistance and early disease recurrence were major contributing factors in the limited survival of patients with acute lymphocytic leukemia (ALL). New chemotherapeutic agents and drug combinations were employed in refractory patients to overcome drug resistance. ##

Acute polyneuropathy after high dose cyt
Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia
✍ Harry Openshaw; Neal E. Slatkin; Anthony S. Stein; David R. Hinton; Stephen J. F 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 699 KB

## BACKGROUND. Peripheral nerve toxicity has been reported but is not a commonly recognized complication of high dose cytosine arabinoside (HDAC) therapy. This study was undertaken to estimate the prevalence and describe the clinical spectrum of acute polyneuropathy associated with HDAC therapy fo

Treatment of acute nonlymphocytic leukem
Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high-dose cytosine arabinoside
✍ Letendre, Louis ;Niedringhaus, Robert D. ;Therneau, Terry M. ;Gastineau, Dennis 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 362 KB 👁 1 views

Effective treatment of the elderly patients (265 years) with acute nonlymphocytic leukemia (ANLL) remains elusive and controversial. In the present study, single-agent Cytosine Arabinoside (AM-C) was administered at an intermediate dose level (500 mg/m2 intravenously [I.V.] I-hour infusion q12 hours